Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo
Back to Resources
  • Videos

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

More Resources

Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases

Read Article

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity

Read Article

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy

Contact Us

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy